A bone implant includes a main body in the form of a hollow body open on both sides in the axial direction. The main body includes a load-bearing material. An encasing body at least partially encases the main body on the outside and includes an in vivo degradable/in vivo resorbable material. Alternatively, the encasing body includes a multiplicity of shaped bodies protruding from the main body in the radial direction that include an in vivo degradable/in vivo resorbable material. A method for producing the bone implant includes an additive manufacturing process. The main body can be at least partially encased by the encasing body in the additive manufacturing process.

An orthopedic implant having a metal surface and a hydroxyapatite layer comprising gallium ions therein disposed on at least part of the metal surface is described. The hydroxyapatite layer has an average crystallite size of less than about 75 nm in at least one direction and dissolves for more than 2 hours in vitro. The hydroxyapatite layer is substantially free of carbonate. The coating, which is formed on a sodium titanate surface, has increased shear strength and tensile strength. The coating is formed by a solution deposited hydroxyapatite process under inert conditions. The pH of the solution varies by less than 0.1 pH unit/hour during coating formation.

An orthopedic implant having a metal surface and a hydroxyapatite layer comprising gallium ions therein disposed on at least part of the metal surface is described. The hydroxyapatite layer has an average crystallite size of less than about 75 nm in at least one direction and dissolves for more than 2 hours in vitro. The hydroxyapatite layer is substantially free of carbonate. The coating, which is formed on a sodium titanate surface, has increased shear strength and tensile strength. The coating is formed by a solution deposited hydroxyapatite process under inert conditions. The pH of the solution varies by less than 0.1 pH unit/hour during coating formation.

An orthopedic implant having a metal surface and a calcium phosphate layer disposed on at least part of the metal surface is described. The calcium phosphate layer has an average crystallite size of less than about 100 nm in at least one direction and dissolves for more than 2 hours in vitro. The calcium phosphate layer is substantially free of carbonate. The coating, which is formed on a sodium titanate surface, has increased shear strength and tensile strength. The coating is formed by a solution deposited hydroxyapatite process under inert conditions. The pH of the solution varies by less than 0.1 pH unit/hour during coating formation.

An orthopedic implant having a metal surface and a calcium phosphate layer disposed on at least part of the metal surface is described. The calcium phosphate layer has an average crystallite size of less than about 100 nm in at least one direction and dissolves for more than 2 hours in vitro. The calcium phosphate layer is substantially free of carbonate. The coating, which is formed on a sodium titanate surface, has increased shear strength and tensile strength. The coating is formed by a solution deposited hydroxyapatite process under inert conditions. The pH of the solution varies by less than 0.1 pH unit/hour during coating formation.

Provided are a bone graft composition and a preparation method thereof, and more particularly, a bone graft composition provided in the form of a putty formulation by mixing calcium phosphate compound particles with hydrogel, having excellent physical properties, which is easy to inject, and which maintains its structure even in an in vivo environment after implantation, thereby enabling sustained release of a drug loaded therein.

Provided are a bone graft composition and a preparation method thereof, and more particularly, a bone graft composition provided in the form of a putty formulation by mixing calcium phosphate compound particles with hydrogel, having excellent physical properties, which is easy to inject, and which maintains its structure even in an in vivo environment after implantation, thereby enabling sustained release of a drug loaded therein.

The present disclosure relates to bone graft substitute formulations with a liquid weight to powder weight ratio (L/P) of about 0.35 to about 0.40. The formulations disclosed herein have significantly longer set times than formulations with lower L/P ratios, and yet the cement resulting from the formulations disclosed herein have comparable dissolution rates to those of formulations having a lower L/P. The present disclosure also relates to kits for making the bone graft substitute formulations and methods of treating bone defects with said formulations.

The present disclosure relates to bone graft substitute formulations with a liquid weight to powder weight ratio (L/P) of about 0.35 to about 0.40. The formulations disclosed herein have significantly longer set times than formulations with lower L/P ratios, and yet the cement resulting from the formulations disclosed herein have comparable dissolution rates to those of formulations having a lower L/P. The present disclosure also relates to kits for making the bone graft substitute formulations and methods of treating bone defects with said formulations.

Methods are provided for modifying a porous surface of an implantable medical device by subjecting the porous surface to a modified micro-arc oxidation process to improve the ability of the medical device to resist microbial growth, to improve the ability of the medical device to adsorb a bioactive agent or a therapeutic agent, and to improve tissue in-growth and tissue on-growth of the implantable medical device.